BCL2 and neoplasm: Here, we provide a summary of how ncRNAs could contribute to such resistance: (1) suppressing the expression and/or release of DAMPs, thereby reducing ICD and contributing to resistance against cancer therapies; (2) inhibiting the expression of drug efflux pumps (e.g., ATP-binding cassette transporters) and anti-apoptotic proteins (e.g., Bcl-2), thereby reducing the susceptibility of tumor cells to chemotherapy and ICD; (3) constructing an immunosuppressive tumor microenvironment, thereby reducing the efficacy of ICD and chemotherapy.